The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 887-893

  Ako, E ^a   Yamashita, Yoshito ^a   Ohira, M ^a   Yamazaki, M ^a   Hori, T ^a   Kubo, N ^a   Sawada, T ^a   Hirakawa, K ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CI 1033; Epidermal growth factor receptor; Esophageal cancer; HER2; Tyrosine kinase inhibitor

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MORPHOLINE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; ESOPHAGUS TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34249934555     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.887     Document Type: Article

References (52)

1. Muller JM, Erasmi H, Stelzner M, Zieren U and Pichlmaier H: Surgical therapy of oesophageal carcinoma. Br J Surg 77: 845-857, 1990. (Pubitemid 20249685)
2. Watanabe H, Kato H and Tachimori Y: Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan. Recent Results Cancer Res 155: 123-133, 2000.
3. Peracchia A, Bonavina L, Ruol A and Stein H: Esophageal cancer: a European perspective. Recent Results Cancer Res 155: 119-122, 2000.
4. Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G and Decker G: Treatment of esophageal carcinoma. Chest 116: 463S-465S, 1999. (Pubitemid 30013158)
5. McManus K, Anikin V and McGuigan J: Total thoracic oesophagectomy for oesophageal carcinoma: has it been worth it? Eur J Cardiothorac Surg 16: 261-265, 1999. (Pubitemid 29443958)
6. Torres AJ, Sanchez-Pernaute A, Hernando F, Diez Valladares L, Gonzalez Lopez O, Perez Aguirre E, Suarez A and Balibrea JL: Two-field radical lymphadenectomy in the treatment of esophageal carcinoma. Dis Esophagus 12: 137-143, 1999. (Pubitemid 29401303)
7. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997. (Pubitemid 27306287)
8. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
9. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997. (Pubitemid 27151960)
10. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254-264, 1996. (Pubitemid 26029205)
11. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
12. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T and Hirakawa K: Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92: 1110-1116, 2005. (Pubitemid 40546677)
13. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N and Kiessling M: Amplification of the epidermal-growth-factorreceptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77, 1994. (Pubitemid 24044796)
14. Kitagawa Y, Ueda M, Ando N, Ozawa S and Kitajima M: Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice. Br J Cancer 72: 865-868, 1995.
15. Pegram MD, Pauletti G and Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65-77, 1998. (Pubitemid 29056086)
16. Harris AL, Nicholson S, Sainsbury R, Wright C and Farndon J: Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr: 181-187, 1992.
17. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR and Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1: 182-185, 1989. (Pubitemid 19038803)
18. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S and Nagura H: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804, 1994. (Pubitemid 24237457)
19. Ozawa S, Ueda M, Ando N, Shimizu N and Abe O: Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169-2173, 1989. (Pubitemid 19136849)
20. Shiga K, Shiga C, Sasano H, Miyazaki S, Yamamoto T, Yamamoto M, Hayashi N, Nishihira T and Mori S: Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res 13: 1293-1301, 1993. (Pubitemid 23334753)
21. Raymond E, Faivre S and Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (suppl 1): 15-23, 2000.
22. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ and Gilmer TM: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94, 2001.
23. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S and Dobrusin EM: Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95: 12022-12027, 1998. (Pubitemid 28460532)
24. Nelson JM and Fry DW: Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276: 14842-14847, 2001.
25. Gieseg MA, de Bock C, Ferguson LR and Denny WA: Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 12: 683-690, 2001. (Pubitemid 32844209)
26. Slichenmyer WJ, Elliott WL and Fry DW: CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28: 80-85, 2001. (Pubitemid 33065113)
27. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, Leopold WR, Ethier SP and Lawrence TS: Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10: 691-700, 2004. (Pubitemid 38180439)
28. Murakami M, Sasaki T, Yamasaki S, Kuwahara K, Miyata H and Chayama K: Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells. Biochem Biophys Res Commun 319: 114-119, 2004. (Pubitemid 38670167)
29. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC and Kaufmann SH: The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61: 739-748, 2001. (Pubitemid 32128641)
30. Hackel PO, Zwick E, Prenzel N and Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11: 184-189, 1999. (Pubitemid 29164032)
31. Moghal N and Sternberg PW: Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 11: 190-196, 1999. (Pubitemid 29164033)
32. Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48, 1998.
33. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC and Yarden Y: Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16: 4938-4950, 1997. (Pubitemid 27348403)
34. Burke CL, Lemmon MA, Coren BA, Engelman DM and Stern DF: Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 14: 687-696, 1997. (Pubitemid 27095860)
35. Reese DM and Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8, 1997. (Pubitemid 27057075)
36. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M and Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467, 1996. (Pubitemid 26151185)
37. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003. (Pubitemid 36687658)
38. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001. (Pubitemid 32946513)
39. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS and Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13: 65-72, 2002. (Pubitemid 34436727)
40. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R and Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000. (Pubitemid 30395817)
41. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263, 2002.
42. Junttila TT, Laato M, Vahlberg T, Soderstrom KO, Visakorpi T, Isola J and Elenius K: Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 9: 5346-5357, 2003. (Pubitemid 37413590)
43. Srinivasan R, Poulsom R, Hurst HC and Gullick WJ: Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185: 236-245, 1998. (Pubitemid 28320044)
44. Rajkumar T, Gooden CS, Lemoine NR, Gullick WJ and Goden CS: Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J Pathol 170: 271-278, 1993. (Pubitemid 23234874)
45. Issing WJ, Heppt WJ and Kastenbauer ER: erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines. Eur Arch Otorhinolaryngol 250: 392-395, 1993. (Pubitemid 23337486)
46. Earp HS III, Calvo BF and Sartor CI: The EGF receptor family-multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans Am Clin Climatol Assoc 114: 315-333, 2003.
47. Tari AM and Lopez-Berestein G: Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-overexpressing cells, respectively. Int J Cancer 86: 295-297, 2000. (Pubitemid 30180828)
48. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000. (Pubitemid 30211165)
49. Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306: 1506-1507, 2004.
50. Allen LF, Lenehan PF, Eiseman IA, Elliott WL and Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29: 11-21, 2002. (Pubitemid 34816061)
51. Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000. (Pubitemid 32197693)
52. Rao GS, Murray S and Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48: 1519-1528, 2000.